GSK’s initial response to the outbreak of COVID-19 has been to make their vaccine adjuvant technology available to scientists and organisations working on promising vaccine candidates and technology platforms. The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protecting more people.
Since announcing collaborations with the University of Queensland and Clover Biopharmaceuticals, GSK have expanded their collaborations and are now collaborating with several companies and research groups across the world, including in the USA and China.
